Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Predictive factors for TKI discontinuation eligibility and treatment-free remission in chronic myeloid leukemia.

Created on 12 Nov 2026

Authors

Takaaki Ono

Published in

International journal of hematology. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

Treatment-free remission (TFR) is an important therapeutic goal in chronic-phase chronic myeloid leukemia. However, not all patients achieve tyrosine kinase inhibitor (TKI) discontinuation eligibility (TDE), and approximately half of those who discontinue therapy experience molecular recurrence. Thus, achieving TDE and maintaining TFR represent related but distinct clinical challenges. Early molecular response kinetics, treatment duration, depth and stability of response, prior TKI resistance, and BCR::ABL1 transcript type have been associated with these outcomes. Emerging biomarkers, including highly sensitive methods, leukemic stem cell characteristics, clonal hematopoiesis, immune-cell profiles, inflammatory cytokines, and host immunogenetic factors, may further refine prediction. Transcriptomic studies, artificial intelligence-based analysis, and mathematical modeling also offer promising approaches for integrating disease biology, host immunity, and treatment dynamics. Whether predictors identified with conventional TKIs apply to asciminib requires further evaluation. Future strategies should integrate longitudinal molecular and biological information to enable safer and appropriately timed TKI discontinuation.

PMID:
43013246
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement